U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07805252) titled 'Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer' on Aug. 26.
Brief Summary: A Phase 1/2, Open-Label, First-in-Human Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumour Activity of ODM-216 in Participants With Advanced Solid Tumours
Study Start Date: Sept. 03
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors Cancer
Intervention:
DRUG: ODM-216
ODM-216
Recruitment Status: RECRUITING
Sponsor: Orion Corporation, Orion Pharma
Published by HT Digital Content Services with permission from Health Daily D...